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The bovine herpesvirus type 1 (BHV-1) open reading frame (ORF) UL3.5 is similar to ORFs found in pseudorabies virus,
infectious laryngotracheitis virus, equine herpesvirus type 1, and varicella zoster virus, but clearly absent from herpes
simplex virus. The published sequence for this ORF predicts a 126-amino-acid (13.2 kDa) protein product with an isoelectric
point of 12.3. We confirmed the UL3.5 sequence, expressed the ORF as a glutathione-S-transferase fusion protein, and made
rabbit antibodies against the purified fusion protein. The antiserum detected a 13-kDa protein in Western blots of MDBK cells
infected with BHV-1, but not with other herpesviruses or uninfected cells. The BHV-1 UL3.5 protein was characterized as a
component of the virion envelope or tegument because it was expressed as a late protein, it was present in the cytoplasm
but not the nucleus of infected cells, and it was removed from purified virions by detergent extraction. © 1998 Academic Press
INTRODUCTION
Bovine herpesvirus type 1 (BHV-1), the etiologic agent
of infectious bovine rhinotracheitits and infectious pus-
tular vulvovaginitis (Gibbs and Rweyemamu, 1977; Wyler
et al., 1989; Yates, 1982), is a member of the Varicellovi-
rus group of the Alphaherpesvirinae subfamily.
The BHV-1 genome comprises single unique long (UL)
and unique short (US) units (Mayfield et al., 1983). The
putative open reading frames (ORFs) identified in the UL
segment are designated UL1 to UL56 because their or-
der, orientation, and sequence are similar to those in the
herpes simplex virus genome (Schwyzer and Acker-
mann, 1996; McGeoch et al., 1988).
BHV-1 also contains a short ORF named UL3.5 be-
tween UL3 and UL4 (Khattar et al., 1995). Similar ORFs
called UL3.5, ORF59, ORF57, and UL3.5, respectively, are
found between the UL3 and UL4 homologs in pseudora-
bies virus (PRV) (Dean and Cheung, 1993), equine her-
pesvirus 1 (EHV-1) (Telford et al., 1992), varicella zoster
virus (Davison and Scott, 1986), and infectious laryngo-
tracheitis virus (Fuchs and Mettenleiter, 1996). Herpes
simplex virus types 1 and 2 (HSV-1, HSV-2), the only
members of the simplexvirus group yet sequenced, have
a UL3/UL4 intergenic area only a third as long as that of
BHV-1 with translational stop codons throughout all six
possible reading frames, suggesting the genomic area
between HSV UL3 and UL4 is translationally inactive
(McGeoch et al., 1988; Worrad and Caradonna, 1988).
Khattar et al., 1995) found the BHV-1 UL3.5 mRNA is
cotranscribed with those of UL1, UL2, and UL3 as part of
a nested set of 39 coterminal mRNAs. This is identical to
the homologous area of PRV as previously described by
Dean and Cheung (1993). The functionality of the PRV
UL3.5 ORF was addressed by Fuchs et al. (1996), who
engineered insertion mutations near each end of UL3.5.
Mutations in the carboxyl terminus had little or no effect
on PRV growth. However, disruption of the N-terminus,
the region of similarity between UL3.5 and its counter-
parts, did not yield viable virus, suggesting the N-termi-
nus, and by inference the UL3.5 protein itself, might be
essential for viral viability. Fuchs et al. (1996) were un-
able to find PRV UL3.5 in virions and concluded that it
was a nonstructural protein.
The purpose of this study was to identify the BHV-1
UL3.5 protein. We showed that it was a 13-kDa late
protein found in the cytoplasm of infected cells and the
envelope or tegument of virions.
MATERIAL AND METHODS
Cells and virus
The Cooper-1 strain of BHV-1 and Madin–Darby bo-
vine kidney (MDBK) cells (ATCC CCL 22) were obtained
from the American Type Culture Collection. Cells were
maintained and all virus was grown in minimum essen-
tial media (MEM; Gibco) supplemented with 5% fetal
bovine serum (FBS; Hyclone).
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Sequencing
The BHV-1 HindIII L fragment, contained in plasmid
pSD 72 (Mayfield et al., 1983), was sequenced as previ-
ously reported (Vlcek et al., 1995). Briefly, random frag-
ments were cloned into bacteriophage M13 and se-
quenced on an Applied Biosystems ABI 370 A automated
sequencer. The entire fragment was sequenced in both
directions with an average depth of character of 7. Pre-
dicted isoelectric points were calculated using the GCG
program Peptidesort (Devereux et al., 1984).
Purification of virions
Confluent MDBK cell monolayers were infected at a
multiplicity of infection (m.o.i.) of 0.1 plaque forming units
(PFU) per cell and incubated at 37°C until 90–100%
cytopathic effect (CPE) was observed. Supernatants
were clarified by low-speed centrifugation. Virions were
further purified by ultracentrifugation essentially as de-
scribed (Misra et al., 1981), except virus was pelleted
through a 40% sucrose cushion and resuspended in
phosphate-buffered saline (PBS) and 0.02% dextrose, pH
7.4, before fractionation on a 20–50% potassium tartrate
gradient. The single, easily visible virus-containing band
was harvested, diluted in PBS, and pelleted through a
40% sucrose cushion. The resulting virus pellet was
resuspended in PBS and examined by electron micros-
copy using uranyl acetate as a negative stain.
Virion fractionation
To isolate the detergent-soluble fraction of BHV-1, tar-
trate-purified virions were further treated with 0.5% NP-40
and 0.5% sodium deoxycholate in NET buffer (150 mM
NaCl, 5 mM EDTA, 50 mM Tris, pH 8) for 15 min at 4°C as
described (Marshall et al., 1986), then centrifuged on a
40% sucrose cushion at 100,000 g for 1 h. Detergent-
solubilized proteins in the top of the sucrose cushion
were suspended in sodium dodecyl sulfate–polyacrylam-
ide gel electrophoresis (SDS–PAGE) sample loading
buffer (Laemmli, 1970). The pellet, containing the deter-
gent-insoluble nucleocapsid proteins, was treated simi-
larly.
Preparation of antibodies against BHV-1 UL3.5
Standard recombinant techniques (Sambrook et al.,
1989) were used to subclone the UL3.5 gene. We di-
gested plasmid pSD 72, which contains the HindIII L
fragment of BHV-1 (Mayfield et al., 1983), with NcoI to
produce a 1009-bp fragment (bases 2410 to 3419) con-
taining the entire UL3.5 and UL4 ORFs in head-to-head
orientation. This DNA fragment was purified by agarose
gel electrophoresis and ligated into the pGEX-KG bacte-
rial expression vector (Guan and Dixon, 1991) to form a
glutathione-S-transferase (GST) fusion protein. The ori-
entation and integrity of the UL3.5 fragment was con-
firmed by restriction analysis and sequencing. A protein
product of approximately 39 kDa estimated by SDS–
PAGE was induced, of which 26 kDa is contributed by the
GST moiety and 13 kDa by UL3.5.
The expression plasmid was transformed into JM109
bacteria (Promega), and cultures were incubated at 37°C
until they reached an OD600 of 0.3. Expression of GST/
UL3.5 was induced with 10 mM isopropyl-b-D-thiogalac-
toside (IPTG). An approximately 39-kDa protein product
was induced by IPTG addition. This protein, presumably
the GST/UL3.5 fusion protein, was partially purified by
glutathione–Sepharose 4B matrix affinity chromatogra-
phy according to the recommendations of the manufac-
turer (Pharmacia), except 10X PBS rather than 1X PBS
was used in the eluant.
The GST/UL3.5 protein was dialyzed overnight against
PBS at 4°C. The dialyzed protein was injected intrader-
mally into a New Zealand white rabbit with Freund’s
complete adjuvant (Sigma). Subsequent boosts were
given at 4- to 6-week intervals with Freund’s incomplete
adjuvant (Sigma). Serum was collected 10–14 days after
each boost and tested for its activity against viral pro-
teins by Western blot analysis.
Western blot analysis
For all experiments other than microsequencing, virus
and infected cell samples were size fractionated on a
15% SDS–PAGE gel and blotted overnight at 25 mV to-
ward the anode onto 0.22-mm nitrocellulose paper (MSI)
using transfer buffer (39 mM glycine, 48 mM Trizma,
0.037% SDS, and 20% methanol) essentially as described
(Burnette, 1981). The nitrocellulose paper was then
washed in distilled water and blocked with 5% skim milk
in PBS for 2 h. Polyclonal antibodies (1:80 dilution) or
monoclonal antibodies (1:10,000 dilution) were incubated
with the blot for 2 h at room temperature. The blot was
washed three times for 15 min with washing buffer (150
mM NaCl, 50 mM Tris–HCl (pH 7.5), 0.05% Tween 20) and
incubated with 1:1000 goat anti-rabbit or goat anti-mouse
Ig (Jackson ImmunoResearch) in 5% skim milk for 1 h.
The blot was washed with washing buffer and developed
with p-nitro blue tetrazolium chloride/5-bromo-4-chloro-
3-indolyl-phosphate-solution (NBT/BCIP solution; 5
Prime 3 3 Prime, Inc.) prepared according to the rec-
ommendations of the company. The color reaction was
stopped with a distilled water wash.
For microsequencing the UL3.5 protein was blotted
onto Immobilon P membrane (Millipore) (LeGendre and
Matsudaira, 1988) by using an SDS-, Tris-, and Glycine-
free buffer system containing 25 mM N-ethylmorpholine
(Sigma) at a pH of 8.3. In this case the UL3.5 protein
migrated toward the cathode because of its high isoelec-
tric point. The transfer was verified by immune staining.
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Temporal characterization of UL3.5 expression
MDBK cell monolayers were inoculated with BHV-1 at
an m.o.i. of 10 PFU/cell and incubated at 37°C for various
times. Monolayers were then washed twice with NET
buffer before lysis with NET buffer and 0.5% NP-40 as
described (Ludwig and Letchworth, 1987). Control cells
were mock inoculated.
To further characterize temporal control of the UL3.5
protein, the DNA synthesis inhibitor phosphonoacetic
acid (PAA) was used as previously described (Ludwig
and Letchworth, 1987). Briefly, PAA (300 mg/ml, Sigma)
was added to the culture medium 2 h before infection.
The infection proceeded for 10 h. Cells were lysed as
described above and all samples were tested by West-
ern blot as described above.
Confocal microscopy
MDBK cells were grown to 90% confluency on cover-
slips, infected with BHV-1 at an m.o.i. of 0.3 PFU/cell, and
incubated for 18 h at 37°C. Infected monolayers were
then washed 33 with PBS and fixed for 1 h with 1%
glutaraldehyde in PBS. Coverslips were washed 33 with
PBS and incubated for 10 min with 0.2% Triton X-100 in
PBS. Afterward, monolayers were washed 53 with PBS
and treated for 10 min with 1 mg/ml sodium borohydride
(NaBH4) in PBS and then washed 53 with PBS. The
NaBH4 treatment was repeated 33.
Anti-UL3.5 polyclonal sera (1:1000) were incubated
with the monolayers for 2 h at 37°C, then washed 53
with PBS before a final PBS wash for 1 h. The secondary
antibody (1:100 goat anti-rabbit IgG linked to Cy 5; Jack-
son ImmunoResearch) was incubated with the monolay-
ers for 1 h at 37°C. Monolayers were washed 53 with
PBS and placed in the dark at 4°C. Coverslips were
mounted onto slides with 200 ml mounting medium (10%
103 PBS, 90% glycerol and 1 mg/ml p-phenylenedi-
amine), sealed with fingernail polish, and kept in the dark
at 4°C until examined. Mounted slides were viewed with
an MRC 600 laser-scanning confocal microscope (Bio-
Rad) with an argon/krypton laser resulting in an excita-
tion frequency of 650–680 nm.
Microsequencing
The UL3.5 protein was prepared by separating viral
envelope proteins in SDS–PAGE and transfer onto Immo-
bilon P membrane (Millipore) (LeGendre and Matsu-
daira, 1988) in an N-ethylmorpholine buffer system. The
protein was subjected to microsequencing by Edman
degradation.
RESULTS AND DISCUSSION
We resequenced the BHV-1 HindIII L fragment from
plasmid pSD 72 (Mayfield et al., 1983). Our sequence for
BHV-1 UL1 to UL3.5 was 99.8% identical to the previously
published sequence (Khattar et al., 1995) despite origi-
nating from the same virus isolate, albeit with a different
passage history. Important differences include the fol-
lowing: (1) Our sequence for UL1 confirmed the pub-
lished sequence (Khattar et al., 1995) except we found a
C rather than a G at position 830, changing methionine
156 to isoleucine. (2) Our sequence for UL2 confirmed the
published sequence (Khattar et al., 1995). However, we
believe there is an undetected frameshift immediately
upstream of the predicted UL2 start site at position 1132.
This would put the ATG at position 842 in frame, elimi-
nate the unusually large intergenic region between UL1
and UL2, and produce a C-terminal sequence similar to
other herpesviral UL2 proteins. (3) Our sequence for UL3
between positions 2129 and 2160 reads CGGCCCTG-
GCGCGGCTGCGGCGCGCGGCTGC rather than the pub-
lished sequence CGGGCCGCGCGCGCTGCGGCGCG-
CGGGCTGC. This changes the UL3 predicted protein
sequence at codons 113–122 from RAARAAARGL to RP-
WRGCGARL. (4) Our UL3.5 sequence exactly matched
the published sequence.
Immune sera against the GST–UL3.5 fusion protein
detected a 13-kDa protein in Western blots of BHV-1-
infected MDBK cells. No protein was detectable when
blots of MDBK cells were infected with PRV, HSV-1, or
EHV-1 or mock infected or when BHV-1-infected cells
were probed with preimmune serum (data not shown).
Efforts to establish the NH2-terminal sequence of this
protein were unsuccessful, suggesting it was N-termi-
nally blocked.
Our rabbit monospecific anti-UL3.5 serum allowed us
to characterize the BHV-1 UL3.5 protein as a late gene
product that was limited to the cytoplasm and incorpo-
rated into the membrane or tegument of virions. The
UL3.5 protein appeared in Western blots 7 h after infec-
tion of MDBK cells with BHV-1 at a m.o.i. of 10. Its amount
increased until 11 h (Fig. 1). UL3.5 production in BHV-1-
infected MDBK cells treated with phosphonoacetic acid
(Seal et al., 1991, 1992; Ludwig and Letchworth, 1987)
during viral growth was severely decreased, as its rela-
tive amount was reduced to a similar extent as that of a
prototypical late protein gC (Ludwig and Letchworth,
1987) (Fig. 2). Our control for early proteins, gB (Ludwig
and Letchworth, 1987), was not affected during PAA
treatment relative to untreated cells. Our conclusion that
UL3.5 is a late gene is consistent with the data of Khattar
et al. (1995), who showed the UL3.5 ORF was transcribed
into a 0.7-kb mRNA that was present at 6 h, but not at 4 h
after infection. In contrast, the PRV UL3.5 ORF was char-
acterized as an early-late gene by Dean and Cheung
(1993).
We used confocal microscopy to show the subcellular
location of the UL3.5 protein. With this sensitive method,
a fluorescence signal was first observable at 5 h but not
3 h after inoculation, supporting expression of BHV-1
UL3.5 as a late protein. Cell monolayers infected at an
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m.o.i. of 0.3 for 18 h had strongly fluorescing cells sur-
rounded by less fluorescent neighboring cells that prob-
ably were secondarily infected, and nonfluorescent un-
infected cells. In about 85% of cells having strong
fluorescence, the signal was homogeneously distributed
throughout the entire cytoplasm (Figs. 3A, 3C, and 3D).
Analysis of several different focal planes demonstrated
that the nucleus remained unstained. In a very few
cases, a strong nuclear fluorescence signal also was
observed (data not shown), perhaps resulting from diffu-
sion of UL3.5 into the nucleus after the integrity of the
nuclear membrane was degraded during the later stages
of infection. No evidence supported the notion of possi-
ble localization of UL3.5 to the Golgi apparatus, endo-
plasmic reticulum, or cytoplasmic filaments (Donaldson
et al., 1990; Huber et al., 1993; Ioshii et al., 1995;
Kuznetsov et al., 1986; Piperno et al., 1987; Steuer et al.,
1990). In a few cells, fluorescent dots were observed
around the periphery of the nucleus in addition to the
cytoplasmic signal (Fig. 3E). Occasionally a punctuate
fluorescence was visible outside the nuclear membrane
7 h after infection (Fig. 3F). Preimmune serum did not
react with infected cells (data not shown).
To assess whether the UL3.5 protein was part of the
BHV-1 virion, we purified BHV-1 by standard methods
and used electron microscopy to show the preparation
contained nothing but whole, intact virions. The copuri-
fication of light particles, which are seen in HSV-1 (Sz-
ilagyi and Cunningham, 1991) and probably BHV-1 (Misra
et al., 1981) infections, was unlikely because centrifuga-
tion through a 40% sucrose cushion was used to sepa-
rate infectious virus from lighter material. The success of
this step was shown by the appearance of only a single
band on potassium tartrate gradients. We analyzed the
purified BHV-1 by Western blot and detected a 13-kDa
protein reacting with anti UL3.5 antibodies. Subsequently
the purified virions were disrupted and fractionated, re-
sulting in supernatant (detergent-soluble) and pellet (de-
tergent-insoluble) fractions. Previous work in our labora-
FIG. 2. Treatment of BHV-1-infected cells with PAA showed BHV-1 gC
and UL3.5, but not gB, were inhibited and thus were late proteins.
Western blots of nontreated (no PAA) and PAA-treated (PAA), BHV-1-
infected (i.) or non-infected (n.i.) MDBK cells 18 h after infection with
BHV-1 were probed with monoclonal antibodies against BHV-1 gB, gC,
or polyclonal antibodies against UL3.5 as indicated. The gB monoclonal
antibody was a mixture of monoclonal antibodies directed against four
epitopes on gB. The amount of gB, a prototypical early protein, was not
reduced by PAA treatment, but the amounts of gC, a prototypical late
protein, and UL3.5 were reduced to nearly unobservable levels by PAA
treatment. The gB and gC gels were 10% acrylamide. The UL3.5 gel was
15% acrylamide.
FIG. 1. Anti UL3.5 antibodies detected a 13-kDa band by Western blot
analysis in BHV-1-infected MDBK cells 7 h postinfection (p.i.). The band
increased thereafter. The protein was absent from noninfected MDBK
cells (n.i.) and cells infected for only 5 h. The numbers above the lanes
indicate the time in hours after infection.
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FIG. 3. Confocal microscopy showed UL3.5 was usually limited to the cytoplasm in BHV-1-infected MDBK cells. Small immunoreactive plaques
appeared in cells infected at m.o.i. 0.03 for 18 h (A) but not in uninfected cells incubated for the same time (B). Cells infected for 6 h had observable
cytoplasmic but not nuclear fluorescence (C), cells infected for 11 h had greater cytoplasmic fluorescence, and most had no nuclear staining (D). A
few cells stained at 18 h had a ring of dots (E) or lobular structures (F) around the nucleus.
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tory has shown this technique solubilizes envelopes and
much of the tegument, but leaves nucleocapsids intact
(Marshall et al., 1986). Since antibodies against well-
characterized nucleocapsid proteins are not yet avail-
able, we used antibodies raised against formaldehyde-
inactivated BHV-1 (Duque et al., 1989) to demonstrate the
separation of BHV-1 into two mutually exclusive frac-
tions. Two detergent-soluble proteins were detectable
only in the detergent-soluble and whole virus sample, but
not in the detergent insoluble fraction (Fig. 4A, *). One
protein was only visible in the whole virus lane and in the
detergent-insoluble fraction (Fig. 4A, 1). The UL3.5 pro-
tein was detected in the detergent-soluble fraction and
only a very faint band was sometimes seen in the deter-
gent-insoluble fraction (Fig. 4B). As an added control,
monoclonal antibodies specific for BHV-1 glycoproteins
B and C (Marshall et al., 1988) were used to probe the
detergent-soluble, detergent-insoluble, and whole virus
samples. As expected, both envelope glycoproteins were
observed in the whole virion sample and in the deter-
gent-soluble fraction, but not in the detergent insoluble
fraction (Figs. 4C and 4D). This leads us to conclude that
UL3.5 is indeed not only a virion protein, but is also likely
associated with the viral envelope or tegument. The
absence of UL3.5 from the nucleocapsid fraction, which
contains intact nucleocapsids and some tegument (Mar-
shall et al., 1986), clearly shows that UL3.5 is not present
in the nucleocapsid. Our results do not show if UL3.5 is
inside or outside the virion membrane, but the absence
of a transmembrane anchor strongly suggests it is not
within the membrane. At this time it is unclear how the
homogeneously distributed cytoplasmic UL3.5 is re-
cruited into the virion. Our results differ from those of
Fuchs et al. (1996), who were unable to detect PRV UL3.5
in purified pseudorabies virions. The large difference
between the sequences of the PRV and the BHV-1 UL3.5
proteins, especially the absence of detectable sequence
similarity in the C-terminal three-quarters of the protein,
suggests that different results might be expected.
Theoretically the inadvertent expression of UL4 ORF,
also present on the cloned plasmid fragment, could
have produced a protein inducing antibodies that react
with BHV-1 in Western blot. This scenario was ruled
out for the following reasons: (1) We verified the cor-
rect orientation of the cloned fragment by restriction
enzyme digestion and the proper fusion between the
GST and UL3.5 genes by sequencing. (2) The UL4 ORF
was in the opposite orientation from all prompters in
the expression plasmid. (3) We purified the GST–UL3.5
fusion protein on glutathione–Sepharose to eliminate
any possibility of immunizing rabbits with contaminat-
ing UL4. (4) Antibodies made against the cloned genes
recognized a protein of about 13 kDa, the predicted
size of the UL3.5 protein. The predicted size of a UL4
protein is 19 kDa. (5) The UL3.5 protein has a predicted
pI of 12.3. The 13-kDa protein that reacted with our
antibody migrated towards the cathode in Western
blots performed in a pH 8.3 buffer free of SDS and Tris.
The predicted pI of UL4 is 6.0, making it unlikely to
migrate toward the cathode under these conditions.
The specific function of BHV-1 UL3.5 and its ho-
mologs are still unknown. Nevertheless, the presence
of the gene in five members of the varicellavirus group,
inability to delete the PRV UL3.5 gene, and presence of
BHV-1 UL3.5 protein in the virion and infected cells
argue UL3.5 mediates one or more important func-
tions.
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